Categories: Clinical TrialNews

Cloudbyz Recognized in Everest Group’s 2024 PEAK Matrix® for Life Sciences EDC Solutions

NAPERVILLE, Ill., Sept. 13, 2024 /PRNewswire/ — Cloudbyz, a leader in cloud-based clinical trial management solutions, is proud to be recognized in the 2024 Everest Group PEAK Matrix® for Life Sciences Electronic Data Capture (EDC) Products. This recognition places Cloudbyz among the top performers in delivering intuitive and scalable EDC solutions globally.

The Everest Group PEAK Matrix® is a renowned industry benchmark that assesses service providers on two critical dimensions: market impact and vision & capability. Cloudbyz’s inclusion in this report underscores its commitment to empowering clinical research with cutting-edge technology designed to optimize data collection, ensure regulatory compliance, and improve trial outcomes.

“We are honored to be acknowledged in Everest Group’s PEAK Matrix® for EDC solutions,” said Dinesh Kashyap, CEO and Founder of Cloudbyz. “This recognition validates our dedication to transforming clinical trials with an integrated, user-friendly platform that addresses the complex needs of life sciences organizations. Our goal is to enable more efficient trials and deliver faster results, ultimately supporting life-saving therapies.”

Key Highlights of Cloudbyz’s EDC Solution:

  • Cloudbyz’s EDC platform is modular and scalable, supporting trials of any size and complexity.
  • It enables real-time data capture, providing insights for more effective decision-making.
  • The platform seamlessly integrates with CTMS and eTMF, ensuring streamlined trial workflows.
  • It ensures compliance with 21 CFR Part 11 and global regulations, reducing compliance risks.
  • Cloudbyz’s EDC unifies clinical data management, integrating ePRO, eConsent, and eCOA for efficient handling.

About Everest Group’s PEAK Matrix® Report The PEAK Matrix® assessment is an industry-standard evaluation that recognizes leading providers based on market impact, portfolio strength, and delivery capability. The report serves as a vital resource for organizations seeking to select technology partners in the clinical development space.

This recognition by Everest Group reaffirms Cloudbyz’s leadership in driving digital transformation for clinical trials, enhancing collaboration among sponsors, contract research organizations (CROs), and investigators to deliver more accurate, patient-centered research.

For more details on Cloudbyz’s recognition in the Everest Group PEAK Matrix® contact Pooja Sood at marketing.team@cloudbyz.com.

About Cloudbyz

Cloudbyz enables life sciences organizations to run faster, more efficient clinical trials with a cloud-based platform built on Salesforce. Offering a fully integrated suite of solutions, including CTMS, EDC, eTMF, and Safety & Pharmacovigilance. Cloudbyz helps drive operational efficiency, improve compliance, and deliver life-saving treatments to patients more quickly. Visit www.cloudbyz.com

View original content:https://www.prnewswire.com/news-releases/cloudbyz-recognized-in-everest-groups-2024-peak-matrix-for-life-sciences-edc-solutions-302247113.html

SOURCE Cloudbyz

Staff

Recent Posts

Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers

Comprehensive Platform Combines Masimo’s Industry-leading Biosensing Capabilities with Snapdragon Wearable Platforms to Expand the Wear…

11 hours ago

Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an…

17 hours ago

KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program

RIYADH, Saudi Arabia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

17 hours ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Updated data show consistent objective response rate of 40% and manageable safety profile in patients…

17 hours ago

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE,…

17 hours ago